U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H10N2O7P2
Molecular Weight 272.0896
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOLEDRONIC ACID ANHYDROUS

SMILES

OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O

InChI

InChIKey=XRASPMIURGNCCH-UHFFFAOYSA-N
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)

HIDE SMILES / InChI

Molecular Formula C5H10N2O7P2
Molecular Weight 272.0896
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zoledronic acid (Reclast, Aclasta, Zometa) is an intravenous, highly potent amino-bisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). Its high affinity to and long half-life in bone, and long duration of action allow for once-yearly administration, which has the potential to improve adherence to therapy. Zoledronic acid once yearly for up to 3 years improved bone mineral density (BMD) at several skeletal sites, reduced fracture risk and bone turnover, and/or preserved bone structure and mass relative to placebo in clinical studies in patients with primary or secondary osteoporosis. While additional benefits were seen when treatment was continued for up to 6 years, as evidenced by a reduced risk of vertebral fractures and higher BMD relative to 3 years’ therapy, there was the minimal advantage of treatment beyond 6 years. Therefore, in patients with low fracture risk, treatment discontinuation should be considered after approximately 5 years’ therapy. Zoledronic acid administered annually or once in 2 years was also effective in preventing bone loss in patients with low bone mass. Zoledronic acid was generally well tolerated, with the most common adverse events (AEs) being transient, mild-to-moderate post-infusion symptoms, which decreased with subsequent infusions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.1 nM [IC50]
97.0 µM [IC50]
92.0 nM [IC50]
62.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zometa

Approved Use

INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy

Launch Date

9.9817921E11
Primary
Zometa

Approved Use

INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy

Launch Date

9.9817921E11
Primary
Zometa

Approved Use

INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy

Launch Date

9.9817921E11
Primary
Zometa

Approved Use

INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy

Launch Date

9.9817921E11
Primary
Zometa

Approved Use

INDICATIONS AND USAGE Hypercalcemia of Malignancy. Zometa® (zoledronic acid for injection) is indicated for the treatment of hypercalcemia of malignancy. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated dequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of Zometa in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Multiple Myeloma and Bone Metastases of Solid Tumors. Zometa is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy

Launch Date

9.9817921E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
264 ng/mL
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLEDRONIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
420 ng × h/mL
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLEDRONIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
39 h
4 mg single, intravenous
dose: 4 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ZOLEDRONIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
16 mg 1 times / 4 weeks multiple, intravenous
Highest studied dose
Dose: 16 mg, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 16 mg, 1 times / 4 weeks
Sources:
unhealthy, 40-79 years
n = 12
Health Status: unhealthy
Condition: cancer
Age Group: 40-79 years
Sex: M+F
Population Size: 12
Sources:
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Other AEs: Skeletal pain, Fever...
Other AEs:
Skeletal pain (30%)
Fever (20%)
Anorexia (20%)
Diarrhea (20%)
Constipation (10%)
Nausea (20%)
Myalgia (20%)
Arthralgia (10%)
Anemia (30%)
Rigors (20%)
Coughing (20%)
Leg edema (10%)
Urinary tract infection (10%)
Fatigue (40%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Arthralgia 10%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Constipation 10%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Leg edema 10%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Urinary tract infection 10%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Anorexia 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Coughing 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Diarrhea 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Fever 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Myalgia 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Nausea 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Rigors 20%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Anemia 30%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Skeletal pain 30%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Fatigue 40%
16 mg single, intravenous
Highest studied dose
Dose: 16 mg
Route: intravenous
Route: single
Dose: 16 mg
Sources:
unhealthy, 54 years (range: 34–73 years)
n = 10
Health Status: unhealthy
Condition: cancer
Age Group: 54 years (range: 34–73 years)
Sex: M+F
Population Size: 10
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
Bisphosphonates induce apoptosis in human breast cancer cell lines.
2000 Apr
Zoledronic acid.
2001
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
2001 Apr
Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
2001 Apr
Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
2001 Apr
Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies.
2001 Apr
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
2001 Apr 1
Adjuvant bisphosphonate therapy: the future.
2001 Aug
Should bisphosphonates be the treatment of choice for metastatic bone disease?
2001 Aug
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
2001 Feb
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
2001 Jul
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
2001 Mar
FDA grants priority review for ZOMETA.
2001 Oct
Bisphosphonates in the treatment of metastatic breast cancer.
2001 Oct
Paget's disease of the spine and its management.
2001 Oct
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.
2001 Oct
New bisphosphonic acid approved by FDA.
2001 Oct 1
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
2001 Sep-Oct
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
2002
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
2002 Aug 15
The role of osteoclastic activity in prostate cancer skeletal metastases.
2002 Feb
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
2002 Feb
Bisphosphonates and osteoporosis.
2002 Feb 28
Bisphosphonates for cancer patients: why, how, and when?
2002 Jul
Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
2002 Jul
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
2002 Jul 4
Novel approaches to the management of bone metastases in patients with breast cancer.
2002 Jun
Gateways to clinical trials.
2002 Oct
Zoledronic acid: new preparation. Just a me-too: no advance in hypercalcemia of malignancy.
2002 Oct
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
2002 Oct 1
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
2002 Sep 1
[Bisphosphonates in bone metastases. Fewer fractures, less pain].
2002 Sep 26
Patents

Patents

Sample Use Guides

The maximum recommended dose of Zometa in hypercalcemia of malignancy is 4 mg. The 4 mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes.
Route of Administration: Intravenous
For the transfection of the T24 human bladder cancer cells, pCMV6 empty vector (OriGene, Rockville, MD, USA) and pCMV6 TAp73 vector were transfected into cells using Lipofectamine™ 2000 (Invitrogen Life Technologies). After 6 h, the medium was refreshed and cultured for 48 h. Then the cells were treated with ZA (200 μM).
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:15:30 UTC 2023
Edited
by admin
on Wed Jul 05 23:15:30 UTC 2023
Record UNII
70HZ18PH24
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOLEDRONIC ACID ANHYDROUS
Common Name English
PHOSPHONIC ACID, (1-HYDROXY-2-(1H-IMIDAZOL-1-YL)ETHYLIDENE)BIS-
Common Name English
ANHYDROUS ZOLEDRONIC ACID
Common Name English
(1-HYDROXY-2-IMIDAZOL-1-YLETHYLIDENE)DIPHOSPHONIC ACID
Systematic Name English
zoledronic acid [INN]
Common Name English
NSC-721517
Code English
Zoledronic acid [WHO-DD]
Common Name English
ZOLEDRONIC ACID [MI]
Common Name English
ZOLEDRONATE
Common Name English
Classification Tree Code System Code
NDF-RT N0000175579
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
WHO-ATC M05BA08
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
FDA ORPHAN DRUG 130899
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
NCI_THESAURUS C443
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
NDF-RT N0000007707
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
Code System Code Type Description
FDA UNII
70HZ18PH24
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
RXCUI
1546014
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID0042668
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
SMS_ID
100000091815
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
INN
7254
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
MERCK INDEX
M11658
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY Merck Index
CHEBI
46557
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
EVMPD
SUB00176MIG
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
CAS
118072-93-8
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
NCI_THESAURUS
C80120
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
NSC
721517
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
EVMPD
SUB12624MIG
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
DRUG BANK
DB00399
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
PUBCHEM
68740
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
DAILYMED
70HZ18PH24
Created by admin on Wed Jul 05 23:15:30 UTC 2023 , Edited by admin on Wed Jul 05 23:15:30 UTC 2023
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
BINDER->LIGAND
Binding to human plasma proteins was low (approximately 22 %) and independent of the concentration of zoledronic acid.
BINDING
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC